Reviewing Hypera (OTCMKTS:HYPMY) and Myovant Sciences (NYSE:MYOV)
Reviewing Hypera (OTCMKTS:HYPMY) and Myovant Sciences (NYSE:MYOV)
Hypera (OTCMKTS:HYPMY – Get Rating) and Myovant Sciences (NYSE:MYOV – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.
Hypera(OTCMKTS：HYPMY-GET Rating)和Myovant Sciences(NYSE：MYOV-GET Rating)都是医疗公司，但哪一家业务更好？我们将根据两家公司的分析师推荐、风险、机构持股、估值、股息、收益和盈利能力的强弱对它们进行比较。
Risk and Volatility
风险和波动性
Hypera has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500.
Hypera的贝塔系数为0.8，表明其股价的波动性比标准普尔500指数低20%。相比之下，Myovant Sciences的贝塔系数为2.28，这表明其股价的波动性比标准普尔500指数高128%。
Profitability
盈利能力
This table compares Hypera and Myovant Sciences' net margins, return on equity and return on assets.
下表比较了Hypera和Myovant Sciences的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Hypera | N/A | N/A | N/A |
| Myovant Sciences | -54.03% | N/A | -29.25% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 金丝桃组 | 不适用 | 不适用 | 不适用 |
| Myovant Science | -54.03% | 不适用 | -29.25% |
Valuation & Earnings
估值与收益
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hypera | $793.81 million | 6.73 | $251.25 million | N/A | N/A |
| Myovant Sciences | $230.97 million | 8.23 | -$205.98 million | ($1.76) | -11.26 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 金丝桃组 | 7.9381亿美元 | 6.73 | 2.5125亿美元 | 不适用 | 不适用 |
| Myovant Science | 2.3097亿美元 | 8.23 | -2.0598亿美元 | ($1.76) | -11.26 |
Hypera has higher revenue and earnings than Myovant Sciences.
Hypera的收入和收益都高于Myovant Sciences。
Insider and Institutional Ownership
内部人与机构持股
0.1% of Hypera shares are owned by institutional investors. Comparatively, 30.6% of Myovant Sciences shares are owned by institutional investors. 1.9% of Myovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Hypera 0.1%的股份由机构投资者持有。相比之下，Myovant Sciences 30.6%的股份由机构投资者持有。Myovant Sciences 1.9%的股份由公司内部人士持有。强大的机构持股表明，捐赠基金、大型基金管理公司和对冲基金相信，一只股票有望实现长期增长。
Analyst Recommendations
分析师建议
This is a summary of recent ratings and target prices for Hypera and Myovant Sciences, as reported by MarketBeat.
据MarketBeat报道，这是Hypera和Myovant Sciences最近的评级和目标价摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hypera | 0 | 0 | 0 | 0 | N/A |
| Myovant Sciences | 0 | 1 | 1 | 0 | 2.50 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 金丝桃组 | 0 | 0 | 0 | 0 | 不适用 |
| Myovant Science | 0 | 1 | 1 | 0 | 2.50 |
Myovant Sciences has a consensus target price of $17.67, suggesting a potential downside of 10.86%. Given Myovant Sciences' higher possible upside, analysts clearly believe Myovant Sciences is more favorable than Hypera.
Myovant Sciences的一致目标价为17.67美元，这意味着潜在的下跌幅度为10.86%。考虑到Myovant Sciences更有可能的上行空间，分析师们显然认为Myovant Sciences比Hypera更有利。
Summary
摘要
Myovant Sciences beats Hypera on 6 of the 11 factors compared between the two stocks.
Myovant Sciences在两只股票的11个指标中有6个击败了Hypera。
About Hypera
关于Hypera
(Get Rating)
(获取评级)
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
Hypera S.A.在巴西是一家制药公司。它提供的处方药有Adacne、Addera、Apri、AmpliumG、请、赛莱他明、Celstone、Celstone Soluspana、Cizax、DECPRAX、衍生CMicro、Micro Drift、Dermol Fusid、Digedrat、双丙胺、双丙沙星、双丙松、双丙松、Emprol XR、Flow、Garasone、Halobx、Lipanon、Moon、Lydian、Macrodantin、MaxSulid、MilGamma、Mioflex-A、Nesina、Novotram、oximax、peridid、Perida混悬剂、Predsim、Pressaliv、Quadriderm、Rizi、Rizi、Softalm、acrotz、tinodin、umma和velunid品牌。该公司还提供Mantecorp护肤品品牌的皮肤化妆品，以及Aprur、Benegrip、Coristina d、Engov、Epocler、Estomazil等品牌的消费者保健产品。此外，该公司还提供Tamarine、Vitasay、BiotôNico Fonoura和Zero-Cal品牌的营养和维生素补充剂产品；以及Neo quí云母、双氯芬酸钠、羟基肼、地比隆、布洛芬、氯沙坦钾、MAL地塞米拉明、奈普生、扑热息痛、西美康、氯雷他定、奥美拉唑、他达和地格列酮品牌下的类似和仿制药。该公司前身为Hypermarcas S.A.，并于2018年2月更名为Hypera S.A.。Hypera S.A.总部设在巴西的São Paulo。
About Myovant Sciences
关于Myovant Science
(Get Rating)
(获取评级)
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
Myovant Sciences Ltd.是一家生物制药公司，为女性和男性开发重新定义的护理。该公司的主导产品是relugolix，这是一种每天口服一次的小分子药物，用作促性腺激素释放激素受体拮抗剂，用于治疗与子宫肌瘤、子宫内膜异位症相关疼痛和晚期前列腺癌相关的月经大出血。它还在开发MVT-602，一种寡肽Kispeptin激动剂，作为辅助生殖的一部分，正在进行治疗女性不孕不育的第二阶段临床试验。Myovant Science Ltd.与辉瑞公司合作，开发和商业化治疗肿瘤学和妇女健康的瑞卢格利克斯。该公司前身为Roivant Endocinology Ltd.，并于2016年5月更名为Myovant Sciences Ltd.。该公司成立于2016年，总部设在英国伦敦。Myovant Science Ltd是Sumitovant Biophma Ltd.的子公司。
Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.
接受Hypera Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Hypera和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。